175 related articles for article (PubMed ID: 28648672)
1. Prognostic significance of interventricular septal thickness in patients with AL amyloidosis.
Cho H; Kim SJ; Shim CY; Hong GR; Ha JW; Kim YR; Yang WI; Chung H; Jang JE; Cheong JW; Min YH; Kim JS
Leuk Res; 2017 Sep; 60():36-43. PubMed ID: 28648672
[TBL] [Abstract][Full Text] [Related]
2. Prognostic and Added Value of Two-Dimensional Global Longitudinal Strain for Prediction of Survival in Patients with Light Chain Amyloidosis Undergoing Autologous Hematopoietic Cell Transplantation.
Pun SC; Landau HJ; Riedel ER; Jordan J; Yu AF; Hassoun H; Chen CL; Steingart RM; Liu JE
J Am Soc Echocardiogr; 2018 Jan; 31(1):64-70. PubMed ID: 29111123
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of right ventricular systolic function in cardiac amyloidosis.
Bodez D; Ternacle J; Guellich A; Galat A; Lim P; Radu C; Guendouz S; Bergoend E; Couetil JP; Hittinger L; Dubois-Randé JL; Plante-Bordeneuve V; Deux JF; Mohty D; Damy T
Amyloid; 2016 Sep; 23(3):158-167. PubMed ID: 27348696
[TBL] [Abstract][Full Text] [Related]
4. European Collaborative Study Defining Clinical Profile Outcomes and Novel Prognostic Criteria in Monoclonal Immunoglobulin M-Related Light Chain Amyloidosis.
Sachchithanantham S; Roussel M; Palladini G; Klersy C; Mahmood S; Venner CP; Gibbs S; Gillmore J; Lachmann H; Hawkins PN; Jaccard A; Merlini G; Wechalekar AD
J Clin Oncol; 2016 Jun; 34(17):2037-45. PubMed ID: 27114592
[TBL] [Abstract][Full Text] [Related]
5. Malnutrition at diagnosis predicts mortality in patients with systemic immunoglobulin light-chain amyloidosis independently of cardiac stage and response to treatment.
Caccialanza R; Palladini G; Klersy C; Cereda E; Bonardi C; Cameletti B; Quarleri L; Montagna E; Foli A; Milani P; Lavatelli F; Marena C; Merlini G
JPEN J Parenter Enteral Nutr; 2014 Sep; 38(7):891-4. PubMed ID: 24072737
[TBL] [Abstract][Full Text] [Related]
6. Light chain type predicts organ involvement and survival in AL amyloidosis patients receiving stem cell transplantation.
Sidiqi MH; Aljama MA; Muchtar E; Buadi FK; Warsame R; Lacy MQ; Dispenzieri A; Dingli D; Leung N; Gonsalves WI; Kumar SK; Kapoor P; Kourelis TV; Hogan WJ; Gertz MA
Blood Adv; 2018 Apr; 2(7):769-776. PubMed ID: 29615413
[TBL] [Abstract][Full Text] [Related]
7. [The importance of cardiac bio-marker assay for the stratification and monitoring of AL amyloidosis patients - single center experience].
Pika T; Lochman P; Vymětal J; Metelka R; Flodr P; Minařík J; Látalová P; Zapletalová J; Bačovský J; Sčudla V
Vnitr Lek; 2013 Sep; 59(9):776-81. PubMed ID: 24073949
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of left atrial function in systemic light-chain amyloidosis: a cardiac magnetic resonance study.
Mohty D; Boulogne C; Magne J; Varroud-Vial N; Martin S; Ettaif H; Fadel BM; Bridoux F; Aboyans V; Damy T; Jaccard A
Eur Heart J Cardiovasc Imaging; 2016 Sep; 17(9):961-9. PubMed ID: 27194782
[TBL] [Abstract][Full Text] [Related]
9. [The usage of Mayo staging system in Chinese patients with primary light chain amyloidosis].
Huang X; Feng J; Zhang C; Shen K; Zhang C; Sun J; Tian Z; Cao X; Zhang L; Zhou D; Li J
Zhonghua Xue Ye Xue Za Zhi; 2016 Apr; 37(4):278-82. PubMed ID: 27093987
[TBL] [Abstract][Full Text] [Related]
10. The impact of dialysis on the survival of patients with immunoglobulin light chain (AL) amyloidosis undergoing autologous stem cell transplantation.
Leung N; Kumar SK; Glavey SV; Dispenzieri A; Lacy MQ; Buadi FK; Hayman SR; Dingli D; Kapoor P; Zeldenrust SR; Russell SJ; Lust JA; Hogan WJ; Rajkumar SV; Gastineau DA; Kourelis TV; Lin Y; Gonsalves WI; Go RS; Gertz MA
Nephrol Dial Transplant; 2016 Aug; 31(8):1284-9. PubMed ID: 26627634
[TBL] [Abstract][Full Text] [Related]
11. Clinical Analysis of Cardiac Involvement in 53 Patients With Multiple Myeloma Coexistent With Light Chain Amyloidosis.
Yu Y; Huang Z; Hu W; Li X; Shen M; Zhang J; Tang R; Chen S; Chen W
Clin Lymphoma Myeloma Leuk; 2020 Aug; 20(8):519-525.e1. PubMed ID: 32389672
[TBL] [Abstract][Full Text] [Related]
12. Pre-transplantation novel agent induction predicts progression-free survival for patients with immunoglobulin light-chain amyloidosis undergoing high-dose melphalan and autologous stem cell transplantation.
Cowan AJ; Klippel ZK; Stevenson PA; Hyun TS; Tuazon S; Becker PS; Green DJ; Holmberg LA; Coffey DG; Gopal AK; Libby EN
Amyloid; 2016 Dec; 23(4):254-259. PubMed ID: 27879147
[TBL] [Abstract][Full Text] [Related]
13. Osteoprotegerin is a significant prognostic factor for overall survival in patients with primary systemic amyloidosis independent of the Mayo staging.
Kastritis E; Gavriatopoulou M; Dimopoulos MA; Eleutherakis-Papaiakovou E; Kanellias N; Roussou M; Pamboucas C; Toumanidis ST; Terpos E
Blood Cancer J; 2015 Jun; 5(6):e319. PubMed ID: 26047389
[TBL] [Abstract][Full Text] [Related]
14. Outcome of Cardiac Light-Chain Amyloidosis in the Era of Novel Therapy - A Single-Center Cohort Study of 227 Patients.
Feng J; Zhang C; Shen K; Sun J; Fang Q; Zhang L; Cao X; Zhou D; Li J; Tian Z
Circ J; 2019 Mar; 83(4):775-782. PubMed ID: 30773521
[TBL] [Abstract][Full Text] [Related]
15. Outcomes for patients with systemic light chain amyloidosis and Mayo stage 3B disease.
Theodorakakou F; Briasoulis A; Fotiou D; Petropoulos I; Georgiopoulos G; Lama N; Kelekis N; Repasos E; Migkou M; Stamatelopoulos K; Dimopoulos MA; Kastritis E
Hematol Oncol; 2023 Oct; 41(4):725-732. PubMed ID: 36974438
[TBL] [Abstract][Full Text] [Related]
16. Induction therapy pre-autologous stem cell transplantation in immunoglobulin light chain amyloidosis: a retrospective evaluation.
Hwa YL; Kumar SK; Gertz MA; Lacy MQ; Buadi FK; Kourelis TV; Gonsalves WI; Rajkumar SV; Go RS; Leung N; Kapoor P; Dingli D; Kyle RA; Russell S; Lust JA; Hayman SR; Lin Y; Zeldenrust S; Dispenzieri A
Am J Hematol; 2016 Oct; 91(10):984-8. PubMed ID: 27341539
[TBL] [Abstract][Full Text] [Related]
17. Identification of prognostic markers in transthyretin and AL cardiac amyloidosis.
Damy T; Jaccard A; Guellich A; Lavergne D; Galat A; Deux JF; Hittinger L; Dupuis J; Frenkel V; Rigaud C; Plante-Bordeneuve V; Bodez D; Mohty D
Amyloid; 2016 Sep; 23(3):194-202. PubMed ID: 27647161
[TBL] [Abstract][Full Text] [Related]
18. Osteopontin: a novel predictor of survival in patients with systemic light-chain amyloidosis.
Kristen AV; Rosenberg M; Lindenmaier D; Merkle C; Steen H; Andre F; Schönland SO; Schnabel PA; Schuster T; Röcken C; Giannitsis E; Katus HA; Frey N
Amyloid; 2014 Sep; 21(3):202-10. PubMed ID: 25007036
[TBL] [Abstract][Full Text] [Related]
19. Ten-year survival after autologous stem cell transplantation for immunoglobulin light chain amyloidosis.
Cordes S; Dispenzieri A; Lacy MQ; Hayman SR; Buadi FK; Dingli D; Kumar SK; Hogan WJ; Gertz MA
Cancer; 2012 Dec; 118(24):6105-9. PubMed ID: 22707405
[TBL] [Abstract][Full Text] [Related]
20. Red blood cell distribution width is a simple and novel biomarker for survival in light-chain amyloidosis.
Yogo T; Okazuka K; Nashimoto J; Uto Y; Sato K; Miyazaki K; Ogura M; Yoshiki Y; Abe Y; Tsukada N; Ishida T; Suzuki K
Int J Hematol; 2019 Oct; 110(4):431-437. PubMed ID: 31236823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]